Distinguished Cancer Physician-Scientist Dr. Herbert (Bob) Pinedo joins Amunix Scientific Advisory Board
March 13, 2017 07:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - March 13, 2017) - Amunix Operating Inc. (Amunix), a biopharmaceutical company focused on the discovery and development of novel biologics, announced today that Dr....
Amunix announces broad alliance with Genentech using XTEN(R) technology
February 15, 2017 07:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - February 15, 2017) - Amunix Operating Inc. (Amunix), a biopharmaceutical company focused on the discovery and development of novel biologics, announced today that it...
Amunix Appoints Fred Hausheer, MD, FACP, as Chief Medical Officer
February 13, 2017 07:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - February 13, 2017) - Amunix Operating Inc., a privately held biotechnology company and developer of a broad portfolio of biopharmaceuticals based on its novel XTEN®...
Biogen exercises option to enter into exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN(R) half-life extension technology
January 05, 2017 12:30 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - January 05, 2017) - Amunix Operating Inc. announced today that Biogen (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license agreement...
IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases
December 19, 2016 07:30 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - December 19, 2016) - Amunix is pleased to announce that Naia Rare Diseases, a biopharmaceutical company developing drugs for Short Bowel Syndrome (SBS) and other rare...
Phase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN(R) Technology
October 17, 2016 09:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - October 17, 2016) - Amunix is pleased to announce that Versartis Inc. (NASDAQ: VSAR) has been granted approval in Japan by the PMDA to initiate enrollment for its...
Long Acting Growth Hormone Based on Amunix' XTEN(R) Technology Completes Enrollment of Phase 3 Trial
September 01, 2016 03:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - September 01, 2016) - Amunix is pleased to announce that Versartis, Inc (NASDAQ: VSAR) has completed enrollment of a Phase 3 study of somavaratan (XTENylated...
Harold E. "Barry" Selick, Ph.D. and Walter H. Moos, Ph.D. Join Amunix Board of Directors
March 03, 2016 17:04 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - March 03, 2016) - Amunix is pleased to announce the appointment Harold E. "Barry" Selick and Walter H. Moos to the company's board of directors. "Barry and...
Amunix Establishes GMP Manufacturing of XTEN(TM) at UN-L BPDF
November 16, 2015 08:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - Nov 16, 2015) - Amunix Operating Inc. (Amunix), a leader in the area of protein half-life extension, today announced that it has completed tech transfer and...
Amunix Announces Extension of Evaluation Agreement With Roche
October 26, 2015 08:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - Oct 26, 2015) - Amunix Operating Inc. (Amunix), a leader in the area of protein half-life extension, today announced that its partner Roche has extended the...